

APPENDIX

10. (Amended) A method according to claim [8 or] 9 wherein [the] said compound is capable of modulating the interaction between a polypeptide which comprises the amino acid sequence Phe/Tyr-Xaa-Xaa-Phe/Tyr-Zaa-Phe/Tyr and PDK1.

13. (Amended) A method of identifying a compound that is capable of mimicking the effect of a 3-phosphoinositide[, for example PtdIns(3,4,5)P<sub>3</sub> or PtdIns(3,4)P<sub>2</sub>,] on the PDK1 or PDK2 activity of [(1)] a PDK1 which has altered substrate specificity derivable by the method of claim 1 [or 12 or (2) a preparation according to claim 2, 24, or 25], the method comprising determining whether said compound activates [a] said PDK1 [or preparation] so that it can phosphorylate a suitable substrate, the activation by said compound being in the absence of a 3-phosphoinositide.

17. (Amended) A polynucleotide encoding a polypeptide as defined in claim 15 [or 16].

18. (Amended) A recombinant polynucleotide suitable for expressing a polypeptide as defined in claim 15 [or 16].

20. (Amended) A method of making a polypeptide as defined in claim 15 [or 16] the method comprising culturing a host cell [as defined in Claim 19] which expresses said polypeptide and isolating said polypeptide.

26. (Amended) A preparation obtainable by the method of claim 24 [or 25].

27. (Amended) A compound identifiable or

identified by the method of [any one of claims] claim 8 [to 13].

32. (Amended) A kit of parts [useful in carrying out a screening method according to any one of claims 8 to 13] for identifying a compound wherein the kit comprises PDK1 and a polypeptide comprising the amino acid sequence Phe/Tyr-Xaa-Xaa-Phe/Tyr-Zaa-Phe/Tyr wherein Zaa represents a negatively charged amino acid residue.